Stepping down against stopping: two decisions treated as one

What can be said with confidence is narrow, and it is worth separating from what is merely plausible. A gradual reduction will not prevent regain: the withdrawal trials establish that ongoing exposure is what holds the weight, and nothing about the schedule on which a drug is removed alters the homeostatic drive that reasserts itself once it is gone. A gradual reduction may nevertheless make the transition more manageable, and a person who finds it so has not been misled. Those two statements are not in tension. Coverage of this subject frequently presents them as though they were, and readers arrive at this department having been told either that tapering is essential or that it is nonsense.

What comes back, and in what proportion

The composition of regained weight is the thinnest part of this literature. None of the three withdrawal designs measured body composition after cessation. The concern most often voiced — that weight lost in a favourable fat-to-lean ratio returns in a less favourable one, so that repeated cycles progressively worsen composition — is physiologically plausible and, in this drug class, entirely unmeasured.

What exists comes from the dietary weight-cycling literature, where the picture is mixed rather than alarming: several studies find that regained weight is disproportionately fat, several find no such asymmetry, and the meta-analytic position is that weight cycling has not been shown to produce a cumulative composition penalty in humans. The Journal regards that as genuinely unresolved rather than as reassurance.

One dataset does bear on it indirectly. In the maintenance trial that randomised exercise, a GLP-1 receptor agonist, both or neither after a diet-induced loss, composition was tracked throughout, and the arms that trained retained a more favourable composition through the maintenance year.¹ That is a statement about maintenance rather than about regain after withdrawal, and it is the closest thing to relevant evidence anybody has.

The case for tapering, stated as fairly as we can

There is no withdrawal syndrome from these agents, no dependence, and no pharmacological reason to reduce gradually rather than to stop. A seven-day half-life produces its own taper: concentrations halve within a week and fall to a few per cent within a month regardless of intent. On the pharmacology alone, a planned taper accomplishes nothing that stopping does not.

The behavioural argument is different and better. Appetite returns over weeks. A person whose dose is reduced in steps experiences that return in stages, while continuing to have some pharmacological support, and has a window in which to establish eating patterns that will have to hold without the drug. A person who stops outright experiences the same return without that window. Whether the window produces better outcomes is an empirical question that has not been asked in a trial.

The Journal’s position is that the behavioural argument is worth making on its own terms and worth not dressing in pharmacological clothing. What a taper cannot do is prevent regain, since the withdrawal trials establish that ongoing exposure is what holds the weight. Presenting a taper as a way of stopping without regaining is a claim the evidence does not support in any form.

The first six weeks after the last injection

Exposure falls on a predictable schedule. A week after a final weekly injection roughly half the steady-state concentration remains; at two weeks a quarter; at four weeks a few per cent. Appetite returns along a curve that lags the concentration curve somewhat, and delayed gastric emptying resolves over a similar interval, so the sensation of early fullness that has been governing meal size for months disappears over about a month.

What people report, and the Journal reports it as report rather than as measurement, is that the appetite return is experienced as abrupt rather than gradual — as a threshold being crossed somewhere in the third or fourth week rather than as a smooth ramp. That is consistent with a non-linear relationship between receptor occupancy and the perceived effect, which is what the dose-response data would predict, and it is not consistent with the exposure curve alone.

Glycaemic parameters follow their own timescale. Fasting glucose responds within days to weeks; HbA1c, which reflects the preceding three months with the recent weeks weighted most heavily, will not show the full consequence of stopping for a full quarter. A panel drawn four weeks after cessation will understate the change, and this is a specific and common misreading. In the trial population with type 2 diabetes, where glycaemic control was a co-primary concern, the treatment effect on HbA1c was of the order of one and a half percentage points, which is the scale of what a cessation eventually undoes.²

What would settle the maintenance question

The Journal’s position is that three trials would resolve almost everything currently argued about in this area, and that all three are straightforward. The first is a dose-reduction design: after a lead-in to target, randomise to full dose, one step down, two steps down, or placebo, and follow for a year with weight as the primary endpoint. It would establish the shape of the descending dose-response curve and would cost a fraction of a pivotal programme.

The second is an interval design: after a lead-in, randomise to weekly, fortnightly and three-weekly administration at the same nominal dose. It would answer the intermittent-schedule question directly and would settle whether the exposure pattern matters independently of average exposure.

The third is a taper design: randomise abrupt cessation against a stepped reduction over twelve weeks, with appetite, eating behaviour and weight measured for a year afterwards. It would test the only argument for tapering that is worth testing.

None of the three is under way as far as the Journal can establish. Readers who know otherwise should write to letters@compoundjournal.com; a registered protocol for any of them would be news in this department.

How the Journal reports a regain figure

Four things accompany every regain number in these pages. Which withdrawal design it comes from, because an off-treatment extension and a randomised placebo switch are different experiments. Whether the lifestyle intervention continued in the arm being described. What the denominator is — regain as a percentage of body weight, as a percentage of the weight lost, or as a final position relative to original baseline, three quantities that are routinely quoted interchangeably. And the follow-up duration, because the regain curve decelerates and a figure at six months is not a figure at a year.

The third of those is where most of the misreporting happens. A statement that participants regained two-thirds is a proportion of loss; a statement that they regained eleven per cent is a proportion of body weight; a statement that they finished 5.6 per cent below baseline is a final position. All three can describe the same arm and they are not interchangeable.

Where a source we are quoting has not stated its denominator, we say that rather than inferring it. Readers who find a regain figure in these pages without its design and its denominator have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

What this piece is not

This is reporting on a body of trial evidence and it is not advice about whether or how to stop taking a medicine. The decision to discontinue an agent prescribed for glycaemic control, cardiovascular risk or kidney disease is materially different from the decision to discontinue one prescribed for weight, and in every case it belongs with a clinician who has seen the person and knows why the drug was started.

Two further notes. Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing here should be read as guidance about using them or about stopping their use. And where this piece describes what clinicians report doing about maintenance dosing, that is description of practice and not a schedule anybody should adopt from a magazine.

The Journal takes correspondence on this subject at letters@compoundjournal.com and factual challenges at standards@compoundjournal.com. Letters describing a personal experience of stopping are read with attention and are published, where they are published, as accounts rather than as evidence — a distinction this department tries hard to preserve in both directions.

What the shortage years demonstrated, at a scale no trial will ever match, is that this class is now being stopped and restarted routinely by circumstance rather than by decision. That is the discontinuation that actually happens, and there is no literature on it at all. The Journal regards documenting it as reporting rather than research, and will keep doing so.